Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0J1KH
|
||||
| Former ID |
DNC007961
|
||||
| Drug Name |
NSC-95397
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [529691] | ||
| Formula |
C14H14O4S2
|
||||
| Canonical SMILES |
C1=CC=C2C(=C1)C(=O)C(=C(C2=O)SCCO)SCCO
|
||||
| InChI |
1S/C14H14O4S2/c15-5-7-19-13-11(17)9-3-1-2-4-10(9)12(18)14(13)20-8-6-16/h1-4,15-16H,5-8H2
|
||||
| InChIKey |
MAASHDQFQDDECQ-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | M-phase inducer phosphatase 2 | Target Info | Inhibitor | [529691] | |
| M-phase inducer phosphatase 1 | Target Info | Inhibitor | [530189] | ||
| Reactome | Cyclin B2 mediated events | ||||
| Cyclin A/B1 associated events during G2/M transition | |||||
| Cyclin A:Cdk2-associated events at S phase entryR-HSA-113510:E2F mediated regulation of DNA replication | |||||
| G0 and Early G1 | |||||
| Polo-like kinase mediated events | |||||
| Activation of ATR in response to replication stress | |||||
| Cyclin E associated events during G1/S transition | |||||
| G1/S-Specific Transcription | |||||
| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | |||||
| Cyclin A:Cdk2-associated events at S phase entry | |||||
| WikiPathways | Senescence and Autophagy in Cancer | ||||
| MAPK Signaling Pathway | |||||
| Retinoblastoma (RB) in Cancer | |||||
| Prostate Cancer | |||||
| Integrated Breast Cancer Pathway | |||||
| Integrated Cancer pathway | |||||
| Mitotic G2-G2/M phases | |||||
| Cell CycleWP707:DNA Damage Response | |||||
| G1 to S cell cycle control | |||||
| S Phase | |||||
| ATM Signaling Pathway | |||||
| Mitotic G1-G1/S phases | |||||
| Cell Cycle | |||||
| Cell Cycle Checkpoints | |||||
| miRNAs involved in DNA damage response | |||||
| miRNA Regulation of DNA Damage Response | |||||
| References | |||||
| Ref 529691 | Bioorg Med Chem. 2008 Oct 1;16(19):9040-9. Epub 2008 Aug 7.Novel naphthoquinone and quinolinedione inhibitors of CDC25 phosphatase activity with antiproliferative properties. | ||||
| Ref 530189 | Bioorg Med Chem Lett. 2009 Aug 1;19(15):4330-4. Epub 2009 May 27.Structure-based de novo design and biochemical evaluation of novel Cdc25 phosphatase inhibitors. | ||||